The usefulness of serum CCL2 in prostate cancer patients was supported by a study using the serum samples of 255 and 124 men with and without prostate cancer, respectively, which reported that serum CCL2 levels in men with prostate cancer were significantly higher than those without. Here, CCL2 is linked to prostate cancer.